Combining a targeted antibody with CAR T cell therapy to treat multiple myeloma
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma
This study is looking at a new way to treat multiple myeloma by using a special antibody called daratumumab together with CAR T cell therapy to see if it can help patients live longer and have fewer relapses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10666472 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for multiple myeloma by combining a therapeutic antibody, daratumumab, with CAR T cell therapy. The goal is to overcome resistance mechanisms that cancer cells develop against existing treatments. The researchers will test the effectiveness of a lower dose of a radioactive version of the antibody alongside CAR T cells in preclinical models. This approach aims to improve patient outcomes by potentially reducing relapses and enhancing survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with relapsed multiple myeloma who have not responded to standard therapies.
Not a fit: Patients with early-stage multiple myeloma or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with relapsed multiple myeloma.
How similar studies have performed: Previous research has shown promise in combining CAR T cell therapy with other treatments, indicating potential for success with this novel approach.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Pichiorri, Flavia — Beckman Research Institute/city of Hope
- Study coordinator: Pichiorri, Flavia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.